Le Lézard
Classified in: Transportation, Health
Subjects: NPT, AVO

American Diabetes Association® Celebrates Culmination of Two Decades of Advocacy on Behalf of Commercial Drivers with Insulin-Treated Diabetes Following Final Rule


ARLINGTON, Va., Sept. 20, 2018 /PRNewswire/ -- The American Diabetes Association (ADA) applauds the U.S. Department of Transportation, Federal Motor Carrier Safety Administration (FMCSA) for its new rule permitting individuals with insulin-treated diabetes to be certified to operate commercial motor vehicles in interstate commerce. The new rule, published in the Federal Register yesterday, is the culmination of more than two decades of advocacy by the ADA to change the rules that govern commercial drivers with diabetes.

(PRNewsFoto/American Diabetes Association)

Since the 1990s, when Congress and FMCSA began studying the feasibility of licensing people who use insulin through waiver and exemption programs, ADA has been pushing for a medically-appropriate system to individually assess people with diabetes. Recognizing the discrimination that results when people are deemed unsafe simply because of how they treat their diabetes, ADA insisted on better, more fair rules. ADA celebrates the achievement of that goal today with FMCSA's final rule.

FMCSA rules apply to most people who operate commercial motor vehicles ? trucks, buses, construction vehicles, delivery vehicles, airport shuttles, etc. ? in interstate commerce. In addition, many employers adopted the rule for their own use in evaluating workers, even if those workers were not directly subject to the rule itself. As a result, a rule that categorically excludes people who use insulin means people with diabetes are kept out of many jobs they are otherwise qualified to perform. The old rule contained a blanket exclusion against insulin use regardless of how well a person managed his or her diabetes. In 2003, FMCSA began granting exemptions to individuals who could satisfy safety criteria and wait out a long and cumbersome application process. The application process involved a period of many months during which the individual could not drive a commercial vehicle, often resulting in loss of income.

The new rule allows individuals on a stable insulin regimen to operate commercial vehicles without needing to obtain an exemption from the government. It provides for an appropriate assessment of diabetes by the individual's treating clinician, followed by examination and certification from a certified medical examiner. "This rule eliminates a longstanding barrier that prevented people with diabetes from fully realizing their potential in the workforce," said Katie Hathaway, JD, Vice President of Legal Advocacy for the American Diabetes Association. "I'm proud of ADA's commitment to this issue and to leading the fight for what's right for people with diabetes. We are so pleased to celebrate this victory alongside those affected by the outdated rule."

ADA's advocacy is reflected in the final rule, which draws on data and recommendations presented in the position statement "Diabetes and Driving," published in ADA's peer-reviewed journal Diabetes Care, and dozens of public comments filed with FMCSA over the years. "Data show people with diabetes do not pose an unacceptable risk to public safety, and blanket bans based on science and medicine from 1970 are not medically supported," said Daniel Lorber, MD, FACP, CDE, chair of the National Advocacy Committee, chair of the Diabetes and Driving writing group and member of the FMCSA Diabetes Expert Panel. "Years of work by ADA staff and volunteers to convince FMCSA to change its rule was grounded in the advances in diabetes science and treatment supported by ADA that allowed for individual assessment and mitigation of risk. Once again, the ADA is fulfilling an important part of its mission 'to improve the lives of all people affected by diabetes'. We are thrilled FMCSA is ending its exemption program not because it doesn't work, but precisely because it has demonstrated the feasibility of identifying qualified drivers and the safety of putting them on the roads."

The final rule was posted in the Federal Register on September 19, 2018.

About the American Diabetes Association
Nearly half of American adults have diabetes or prediabetes; more than 30 million adults and children have diabetes; and every 21 seconds, another individual is diagnosed with diabetes in the U.S. Founded in 1940, the American Diabetes Association (ADA) is the nation's leading voluntary health organization whose mission is to prevent and cure diabetes, and to improve the lives of all people affected by diabetes. The ADA drives discovery by funding research to treat, manage and prevent all types of diabetes, as well as to search for cures; raises voice to the urgency of the diabetes epidemic; and works to safeguard policies and programs that protect people with diabetes. In addition, the ADA supports people living with diabetes, those at risk of developing diabetes, and the health care professionals who serve them through information and programs that can improve health outcomes and quality of life. For more information, please call the ADA at 1-800-DIABETES (1-800-342-2383) or visit diabetes.org. Information from both of these sources is available in English and Spanish. Find us on Facebook (American Diabetes Association), Twitter (@AmDiabetesAssn) and Instagram (@AmDiabetesAssn).

Contact: 

Alex Day, 703-253-4843


[email protected]

 

SOURCE American Diabetes Association


These press releases may also interest you

at 10:45
The "PCR Markets. Forecasts for qPCR, dPCR, Singleplex & Multiplex Markets and by Application, Product and Place. With Executive and Consultant Guides, Including Customized Forecasting and Analysis. 2023 to 2027" report has been added to...

at 10:30
The "Licensing Deals in Biotechnology 2019-2024" report has been added to ResearchAndMarkets.com's offering. Licensing Deals in Biotechnology provides a detailed understanding and analysis of how and why companies enter licensing deals. Fully...

at 10:30
The "Molecular Diagnostics for Cancer: Markets Forecasts by Cancer Type, Product, and Place with Executive & Consultant Guides and Customization. 2023 to 2027" report has been added to ResearchAndMarkets.com's offering. Exciting technical...

at 10:30
Closed System Transfer Devices Market in terms of revenue was estimated to be worth $1.1 billion in 2024 and is poised to reach $2.5 billion by 2029, growing at a CAGR of 14.5% from 2024 to 2029 according to a new report by MarketsandMarketstm. The...

at 10:30
RIVANNA®, a developer of imaging-based medical solutions, names Craig Loomis as senior director of product management. With over 25 years of extensive experience in global product development and commercialization within the healthcare sector, Mr....

at 10:10
The group division of Ameritas proudly announces its 17th consecutive certification as a BenchmarkPortal Center of Excellence, solidifying its position as a leader in customer service and support excellence. This prestigious recognition for 2023...



News published on and distributed by: